Freedom from Long-Term Polymer Exposure

2.5 ✓

SYNERGY™ Stent offers peace of mind knowing that the polymer is gone shortly after the drug is completely eluted at 3 months[1]

Synchronous Drug Elution and Polymer Absorption[1]



Polymer Absorption Rates in Perspective

Nobori™[3] and BioMatrix Flex™[4] Stents



Absorption time > 9 months

Orsiro™[5] Stent



Absorption time > 15 months

Absorb™ BVS[4] Scaffold



Absorption time > 24 months

คณะกรรมการพิจารณาผลการประกวดราคาอิเล็กทรอนิกส์

๑.ลงชื่อ.....ประธานกรรมการ

๒.ลงชื่อ.....กรรมการ

๓.ลงชื่อ.....กรรมการ

EVOLVE II Clinical Trial

SYNERGY™ STENT

Broadest and most complex patient population ever studied in a U.S. Pivotal Trial

EVOLVE II Clinical Trial[4] Study Overview:
Patients (n=684) were randomized 1:1 to SYNERGY or PROMUS Element™ Plus Stent Systems with ≤3 native coronary artery lesions in ≤2 major epicardial vessels, lesion length ≤34 mm, RVD ≥2.25 to ≤4.0 mm, %DS≥ 50 to <100 (excluded LM disease, SVG, CTO, or recent STEMI)

EVOLVE II Clinical Trial A More Comers Study[4]



Primary Endpoint of Target Lesion Failure[6] (TLF) Met



ZERO definite ST events in SYNERGY arm after 24 hours[4]

Stent Thrombosis (ST) *(Definite/Probable)* Through 12-Months[4]



4. EVOLVE II Clinical Trial presented by Dean Kereiakes, MD at AHA 2014. 1,684 patients were randomized 1:1 to SYNERGY or PROMUS Element™ Plus Stent Systems. Graph shows TLF Per Protocol (PP) and MI, TLR, CD shown for the Intent-to-Treat (ITT) population. ITT TLF for SYNERGY Stent = 6.7%, and for PROMUS Element Stent =6.4%, respectively (p=0.0005 for non-inferiority). The SYNERGY Stent is an investigational device and not for sale in the U.S. or Japan.

5. Medically-Treated Diabetes Mellitus

6. TLF: Ischemia-driven TLR, MI related to the target vessel, or any cardiac death. To conclude non-inferiority, the primary endpoint was required to have been met in both intent-to-treat and per protocol patient populations.

7. Per protocol spontaneous MI is defined as rise and/or fall of cardiac biomarkers with one value >99th percentile of the URL + with evidence of myocardial ischemia. Peri-PCI MI is defined as one of the following: i) Troponin elevations within 48 hours of PCI (based on CK-MB >3X URL), ii) new pathological Q waves, or iii) autopsy evidence of acute MI.

8. Meredith T, AM, MBBS, PhD. PCR 2014. Only the "full dose" SYNERGY Stent results are shown.

คณะกรรมการพิจารณาผลการประกวดราคาอิเล็กทรอนิกส์

๑.ลงชื่อ.....ประธานกรรมการ

๒.ลงชื่อ.....กรรมการ

๓.ลงชื่อ.....กรรมการ

EVOLVE Clinical Trial
SYNERGY™ STENT

Outstanding Safety and Efficacy at 3-Years

Early and long-term data demonstrates exceptional results[8]

0% TLR from 6 Months to 3-Years[8]



1.1% TLR and 0% ARC ST at 3-Years[8]



One NQWMI in the SYNERGY group was periprocedural. The remaining 2 NQWMI in the SYNERGY arm were considered unrelated to the study device: one at day 347 due to anemia and a major GI bleed, and one at day 364 subsequent to respiratory failure in a patient with severe COPD—enzymes were checked indicating that a NQWMI had occurred. The one death was of an unknown cause at day 472 and adjudicated as a Cardiac Death. Safety Population.

คณะกรรมการพิจารณาผลการประกวดราคาอิเล็กทรอนิกส์

๑.ลงชื่อ.....ประธานกรรมการ

๒.ลงชื่อ.....กรรมการ

๓.ลงชื่อ.....กรรมการ

SYNERGY™ Stent
Clinical Program and Research*

Addressing full spectrum of cardiovascular disease complexity



SYNERGY *Everolimus-Eluting Platinum Chromium Coronary Stent System*

MONORAIL™ CATHETER—PRODUCT ORDERING INFORMATION

ø (mm)	STENT LENGTH (mm) 8	12	16	20	24	28	32	38	Overexpansion Capabilities
2.25	H7493926208220	H7493926212220	H7493926216220	H7493926220220	H7493926224220	H7493926228220	H7493926232220	H7493926238220	3.50
2.50	H7493926208250	H7493926212250	H7493926216250	H7493926220250	H7493926224250	H7493926228250	H7493926232250	H7493926238250	3.50
2.75	H7493926208270	H7493926212270	H7493926216270	H7493926220270	H7493926224270	H7493926228270	H7493926232270	H7493926238270	3.50
3.00	H7493926208300	H7493926212300	H7493926216300	H7493926220300	H7493926224300	H7493926228300	H7493926232300	H7493926238300	4.25
3.50	H7493926208350	H7493926212350	H7493926216350	H7493926220350	H7493926224350	H7493926228350	H7493926232350	H7493926238350	4.25
4.00	H7493926208400	H7493926212400	H7493926216400	H7493926220400	H7493926224400	H7493926228400	H7493926232400	H7493926238400	5.75

* Boston Scientific is not responsible for the collection, analysis or reporting of the investigator-sponsored research output which is the sole responsibility of the investigators. Boston Scientific's involvement in investigator-sponsored research is limited to providing financial support for research that advances medical and scientific knowledge about our products.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Information contained herein is for distribution outside the US, France, and Japan only.

All cited trademarks are the property of their respective owners.

Boston Scientific
Advancing science for life™

bostonscientific-international.com

IC-222116-AD NOV2014

Boston Scientific (Thailand) Ltd.

คณะกรรมการพิจารณาผลการประกวดราคาอิเล็กทรอนิกส์

๑.ลงชื่อ.....ประธานกรรมการ

๒.ลงชื่อ.....กรรมการ

๓.ลงชื่อ.....กรรมการ